3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
5
INDUSTRY
3
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Estrogen Receptor Positive Breast Cancer
1
Interventions
Cyclophosphamide
4
Cisplatin
3
pembrolizumab
2
fludarabine
2
apatinib
2
XELOX
2
S 1 (combination)
2
Paclitaxel
2
Oxaliplatin
2
Nivolumab
2
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
2
Irinotecan
2
Injections
2
Gemcitabine
2
Fulvestrant
2
Epirubicin
2
Drug Therapy
2
Boron Neutron Capture Therapy
2
titanium silicide
1
tislelizumab
1
surufatinib
1
sintilimab
1
pegfilgrastim
1
nimotuzumab
1
ipatasertib
1
ferumoxides
1
famitinib
1
eribulin
1
dalpiciclib
1
dactolisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
OTHER_GOV
×
capivasertib
×
Clear all
NCT01992952
2025-11-26
FAKTION
Velindre NHS Trust
Phase 1/2
Active not recruiting
149 enrolled